Combination of Dasatinib and Dexamethasone targets the myeloma plasma cell through its interaction with the bone marrow microenvironment
Dexamethasone therapy has been the backbone of myeloma treatment for the last few decades. Despite advances in chemotherapy, myeloma continues to be incurable and all patients eventually relapse with progressive disease. Cell adhesion mediated drug resistance and a permissive bone marrow microenviro...
| Main Author: | |
|---|---|
| Published: |
King's College London (University of London)
2012
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628149 |